6月23日 - ** 临床阶段肿瘤学公司 Boundless Bio（BOLD.O）的股价在盘前交易中大涨约72%，至2.4美元
** 该公司将与生物技术公司Serapha Bio通过全股票交易完成合并
** 预计该公司股东将持有合并后公司约3.7%的股份，而Serapha股东将持有约96.3%的股份
** 合并后实体将命名为Serapha Bio, Inc.，预计将在纳斯达克上市，股票代码为“AATD”
** 在交易完成前，该公司预计将向合并前的股东宣布派发现金股息，以分配超额净现金
** 为支持此次合并，Serapha通过由RA Capital Management和RTW Investments共同领投、Janus Henderson Investors提供支持的 私募融资筹集了2.3亿美元
** 今年迄今，BOLD股价已上涨约17%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.